Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17596634 | 0.84 | CES2 (0.52) | CES2CES1CNR1CNR2NAAA | |
| SCHEMBL11402447 | 0.84 | CYP3A4 (0.53) | CES2CES1CNR1CNR2NAAA | |
| SCHEMBL9239192 | 0.83 | NAAA (0.53) | CES2CES1CNR1CNR2NAAA | |
| SCHEMBL4207067 | 0.80 | LAP3 (0.55) | CES2CES1CNR1CNR2POLB | |
| SCHEMBL9232927 | 0.79 | NAAA (0.68) | NAAA | |
| SCHEMBL27526912 | 0.79 | MME (0.54) | CES2CES1CNR1CNR2 | |
| SCHEMBL1173971 | 0.79 | PKM (0.57) | CES2CES1CNR1CNR2NAAA | |
| Hydrochloric Acid SCHEMBL11651001 | 0.78 | CNR1 (0.46) | CNR1CNR2TACR1TACR3NAAA | |
| SCHEMBL22118182 | 0.78 | MAPK1 (0.51) | CNR1NAAA | |
| SCHEMBL13913575 | 0.77 | KMT2A (0.55) | CES2CES1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338243-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-24 | — | — | US | disclosed |
| US-20220235062-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-28 | — | — | US | disclosed |
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3191488-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016039983-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235062-A1 | P2X7 MODULATORS | P2RX7, P2RX4, P2RX1 | CES2 2229/4885CES1 1537/4885CNR1 66/4885 |
| US-12338243-B2 | P2X7 modulators | P2RX7, P2RX4, P2RX1 | CES2 2229/4885CES1 1537/4885CNR1 66/4885 |
| US-20180118749-A1 | P2X7 MODULATORS | P2RX7, P2RX3, P2RX1 | CES2 3335/4885CES1 1330/4885CNR1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.